BioTime and its subsidiary companies are committed to delivering novel products based on regenerative medicine to patients with serious diseases and degenerative conditions for which there are no cures.
Asterias Biotherapeutics, Inc., is advancing its pluripotent stem cell-based therapies in the world’s first human embryonic stem cell-based human clinical trial. AST-OPC1 is in a Phase I trial for spinal cord injury rehabilitation and AST-VAC2 is advancing toward clinical development for non-small cell lung cancer.
OncoCyte Corporation is focused on developing proprietary diagnostic products to meet unmet needs in the detection and screening of lung, breast and bladder cancer.
AgeX Therapeutics, Inc. (“AgeX”) is a biotechnology company focused on the emerging field of interventional gerontology. Its technology platform is built upon a modern understanding of the molecular basis of cellular immortality and regenerative biology. Leveraging technology licensed from BioTime, Inc. as well as Geron Corporation, AgeX is leading the development of novel therapeutics targeting some of the largest market opportunities associated with an aging population.